EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Exploring the Effectiveness of Adjunctive Cenobamate in Focal Epilepsy: A Time-Based Analysis

Roberta Roberti, Gianfranco Di Gennaro, Vittoria Cianci, Alfredo D'Aniello, Carlo Di Bonaventura, Giancarlo Di Gennaro, Francesco Fortunato, Edoardo Fronzoni, Alessandra Morano, Angelo Pascarella, Eleonora Rosati, Ilaria Sammarra und 2 weitere

CNS Drugs · 2025-05 · 39 (5) · 513-523

DOI: 10.1007/s40263-025-01166-8 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift CNS Drugs, online erschienen am 27.02.2025. Verfasst von Roberta Roberti und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Sciences, University of Catanzaro "Magna Græcia", Viale Europa, 88100, Catanzaro, Italy. Hauptthemen laut MEDLINE: Epilepsies, Partial, Anticonvulsants, Carbamates, Chlorophenols. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Angelini Pharma, Università degli studi "Magna Graecia" di Catanzaro.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: A growing body of evidence supports the effectiveness of cenobamate (CNB). This study aimed to assess the clinical response to add-on CNB through a time-to-event approach and explore the potential contribution of the concomitant classes of antiseizure medications (ASMs) to improve CNB clinical use. PATIENTS AND METHODS: This study is a subgroup analysis of a larger retrospective, multicenter study on adults with focal-onset seizures participating in the Italian Expanded Access Program at five pre-established centers. The primary endpoint was the time-to-baseline seizure count; secondary endpoints included the rates of seizure response, seizure freedom (defined as no seizures' occurrence since at least the previous follow-up visit), treatment discontinuation, and adverse events (AEs). RESULTS: Data on 92 participants were extracted, with a median age of 44 (first quartile (Q1)-third quartile (Q3): 29.25-50.75) years. The number of seizures recorded during the 90-day baseline was reached by 59/92 (64.1%) subjects during the 12-month follow-up. A higher, but not statistically significant probability of reaching the baseline seizures count was shown in the subgroups of subjects taking CNB with sodium channel blockers (SCBs) (hazard ratio [HR] 2.75; 95% confidence interval [CI] 0.79-9.61, p = 0.112) and both SCBs and GABAergics (HR 1.48; 95% CI 0.43-5.09, p = 0.536) compared with subjects taking GABAergics without SCBs. At 12 months, the rates of seizure response, seizure-freedom, and treatment discontinuation were 42.0%, 13.6%, and 23.9%, respectively. A total of 47/92 (51.1%) subjects experienced AEs (mainly somnolence, dizziness, and balance disorders) at a median time of 61 (Q1-Q3: 30-101) days. There was a higher, but not statistically significant risk of AEs occurrence in subjects treated with both SCBs and GABAergics and in those taking SCBs without GABAergics (HR 2.24; 95% CI 0.51-9.82, p = 0.286 and HR 1.40; 95% CI 0.31-6.39, p = 0.661, respectively) compared with those taking GABAergics without SCBs. The main limitations are the retrospective design and the small sample size. CONCLUSIONS: This time-to-event analysis added new insights to the currently available evidence about the real-world effectiveness of add-on CNB. Explorative estimates suggested favorable trends for subjects treated with concomitant GABAergics and without SCBs, who seemed to reach baseline seizure count and experience AEs less frequently and later than subjects treated with other concomitant ASMs. Further studies are needed to identify the best combinations of CNB with other ASMs to maximize seizure control and tolerability.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epilepsies, PartialAnticonvulsantsCarbamatesChlorophenolsHumansMaleFemaleRetrospective StudiesAdultMiddle AgedTreatment OutcomeDrug Therapy, CombinationSeizuresFollow-Up StudiesTime FactorsTetrazoles

Substanzen

AnticonvulsantsCenobamateCarbamatesChlorophenolsTetrazoles

Autor:innen und Institutionen

  • Department of Health Sciences, University of Catanzaro "Magna Græcia", Viale Europa, 88100, Catanzaro, Italy.
  • Regional Epilepsy Center, "Bianchi-Melacrino-Morelli" Great Metropolitan Hospital, Reggio Calabria, Italy.
  • IRCCS Neuromed, Pozzilli, Italy.
  • Department of Human Neurosciences, Sapienza University, Rome, Italy.
  • Institute of Neurology, Department of Medical and Surgical Sciences, Magna Graecia University of Catanzaro, Catanzaro, Italy.
  • Neurology 2, Careggi University Hospital, Florence, Italy.

ORCID-Profile: Emilio Russo

Förderung

  • Angelini Pharma
  • Università degli studi "Magna Graecia" di Catanzaro

Zitieren

APA

Roberti, R., Di Gennaro, G., Cianci, V., D'Aniello, A., Di Bonaventura, C., Di Gennaro, G., Fortunato, F., Fronzoni, E., Morano, A., Pascarella, A., Rosati, E., Sammarra, I., Russo, E., & Lattanzi, S. (2025). Exploring the Effectiveness of Adjunctive Cenobamate in Focal Epilepsy: A Time-Based Analysis. CNS Drugs, 39(5), 513-523. https://doi.org/10.1007/s40263-025-01166-8

Vancouver

Roberti R, Di Gennaro G, Cianci V, D'Aniello A, Di Bonaventura C, Di Gennaro G, et al. Exploring the Effectiveness of Adjunctive Cenobamate in Focal Epilepsy: A Time-Based Analysis. CNS Drugs. 2025;39(5):513-523. doi:10.1007/s40263-025-01166-8

BibTeX
@article{Roberti2025,
  author = {Roberti, Roberta and Di Gennaro, Gianfranco and Cianci, Vittoria and D'Aniello, Alfredo and Di Bonaventura, Carlo and Di Gennaro, Giancarlo and Fortunato, Francesco and Fronzoni, Edoardo and Morano, Alessandra and Pascarella, Angelo and Rosati, Eleonora and Sammarra, Ilaria and Russo, Emilio and Lattanzi, Simona},
  title = {Exploring the Effectiveness of Adjunctive Cenobamate in Focal Epilepsy: A Time-Based Analysis},
  journal = {CNS Drugs},
  year = {2025},
  volume = {39},
  number = {5},
  pages = {513--523},
  doi = {10.1007/s40263-025-01166-8}
}
Kostenlos starten →